Skip to main content
. 2023 Apr 25;29(2):97–103. doi: 10.5114/pedm.2023.124266

Table III.

Comparison of baseline parameters between SH-T1 patients who develop OH and with persistent SH at the end of follow-up

Parameter OH
(n= 6)
Mean ±SD (range)
Persistent SH
(n= 31)
Mean ±SD (range)
p-value
(* significance)
Age (years) 8.5 ±1.6 (6.1–9.7) 9.4 ±3.2 (3.3–14.5) 0.52
Sex (F), n(%) 4 (66.7) 17 (54.8) 0.48
TSH (µlU/ml) baseline 11.6 ±3.8 (7.5–17.7) 6.4 ±2.6 (4.4–13.1) 0.002*
fT4 (µlU/ml) baseline 0.0±0.1 (0.9–1.0) 1.2 ±0.2 (0.8–1.7) 0.15
BMI Z-score baseline 1.2 ±0.7 (0.0–2.0) –0.1 ±1.4 (from –0.3 to 1.9) 0.03*
ΔBMI Z-score –0.1 ±0.4 (from –0.8 to 0.3) 0.2 ±0.9 (from –2.2 to 2.1) 0.47
hSDS baseline 0.3 ±0.7 (from –1.0 to 1.0) 0.0 ±1.5 (from –2.9 to 4.3) 0.59
ΔhSDS 0.2 ±0.5 (from –0.3 to 0.7) 0.1 ±1.9 (from –2.2 to 2.9) 0.73
Abs (+), n(%) 1 (16.7) 11 (35.5) 0.10

SH – subclinical hypothyroidism; OH – patients with overt hypothyroidism; F – female sex; N – number; SD – standard deviation’ FU – follow-up; TSH – thyroid-stimulating hormone, fT4 – free thyroxine; hSDS – height standard deviation score; BMI – body mass index; Abs – antithyroid autoantibodie